Bavituximab Anti-Cancer Program: The company launched the Phase II
cancer clinical program for bavituximab during the quarter and achieved a
number of other clinical and preclinical advancements.
-- Initiated patient dosing in a Phase II combination therapy trial of
bavituximab and docetaxel in patients with advanced breast cancer
within 14 days of study initiation.
-- Received regulatory approval to begin two additional Phase II
bavituximab combination therapy trials -- one in combination with
carboplatin and paclitaxel in patients with advanced breast cancer and
another in combination with carboplatin plus paclitaxel in patients
with non-small cell lung cancer (NSCLC). Both trials are preparing to
begin enrolling patients shortly.
-- A bavituximab cancer investigator presented data at a leading
scientific meeting on anti-angiogenic agents -- the 10th Annual
International Symposium on Anti-Angiogenic Agents (Angio 2008) --
highlighting the positive clinical experience to date with
-- A preclinical study published in Clinical Cancer Research confirmed
bavituximab's ability to target tumor blood ves
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved